menu
    • menu

    Company profile for 858 Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell ge...
    858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    858 TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4757 Nexus Center Drive, Suite 150 San Diego, CA 92121
    Telephone
    Telephone
    +1 (858) 987-8380
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://8five8tx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    858 Therapeutics Announces FDA Fast Track Designation For PARG
    858 Therapeutics Announces FDA Fast Track Designation For PARG

    08 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-08/858-therapeutics-announces-fda-fast-track-designation-for-parg-inhibitor-etx-19477-for-the-treatment

    PHARMIWEB
    08 Jan 2026
    Share Share
    858 Therapeutics Announces $50 Million Series B Financing
    858 Therapeutics Announces $50 Million Series B Financing

    26 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926331123/en

    BUSINESSWIRE
    26 Sep 2024
    Share Share
    858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR
    858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR

    14 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240314459077/en

    BUSINESSWIRE
    14 Mar 2024
    Share Share
    858 laid off select researchers, closed New York site
    858 laid off select researchers, closed New York site

    16 Nov 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/versant-backed-858-recently-laid-select-researchers-and-closed-new-york-site-tied-gotham

    Max Bayer FIERCE BIOTECH
    16 Nov 2023
    Share Share
    858 Therapeutics Expands Board of Directors and Leadership Team
    858 Therapeutics Expands Board of Directors and Leadership Team

    05 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220405005256/en

    BUSINESSWIRE
    05 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search